overall, our operating income performance translated to earnings per share of $num-one for the fourth quarter, up num-two% and $num-three for the full year, up num-four%.
driven by the strength in operating income, fourth quarter earnings per share grew num-one% to $num-two with the full year up num-three% to $num-four.
overall, our operating income performance translated to earnings per share of $num-one for the fourth quarter, up num-two% and $num-three for the full year, up num-four%.
driven by the strength in operating income, fourth quarter earnings per share grew num-one% to $num-two with the full year up num-three% to $num-four.
we delivered double-digit sales and earnings growth in a challenging year.
we currently anticipate total company sales between $num-one billion and $num-two billion which translates to sales growth of between num-three% and num-four%.
we expect to grow our total company volumes by num-one% to num-two% next year, outpacing overall protein consumption growth.
on capital loan, we expect to invest $num-one billion in fiscal year year-seven with a disproportionate share focused on new capacity and automation objectives.
in pursuit of our priority to build financial strength and flexibility, we have substantially de-levered our business over the past num-one months, reducing leverage to num-two times net debt to adjusted ebitda as we paid down $num-three billion of debt while growing our earnings and cash flow.
we expect num-one% to num-two% volume growth on a year-over-year basis as we work to optimize our existing footprint and run our plants full.
we currently anticipate capex spending of approximately $num-one billion during fiscal year-seven, an increase of roughly $num-two million.
liquidity is expected to significantly exceed our target, while net leverage is expected to remain well below num-one times net debt to adjusted ebitda.
in international and other, we expect margins of num-one% to num-two% as capacity expansions and strong global demand support volume growth and improved profitability.
we expect to grow our total company volumes by num-one% to num-two% next year, outpacing overall protein consumption growth.
on capital loan, we expect to invest $num-one billion in fiscal year year-seven with a disproportionate share focused on new capacity and automation objectives.
in pursuit of our priority to build financial strength and flexibility, we have substantially de-levered our business over the past num-one months, reducing leverage to num-two times net debt to adjusted ebitda as we paid down $num-three billion of debt while growing our earnings and cash flow.
we expect num-one% to num-two% volume growth on a year-over-year basis as we work to optimize our existing footprint and run our plants full.
we currently anticipate capex spending of approximately $num-one billion during fiscal year-seven, an increase of roughly $num-two million.
liquidity is expected to significantly exceed our target, while net leverage is expected to remain well below num-one times net debt to adjusted ebitda.
in international and other, we expect margins of num-one% to num-two% as capacity expansions and strong global demand support volume growth and improved profitability.
overall, our operating income performance translated to earnings per share of $num-one for the fourth quarter, up num-two% and $num-three for the full year, up num-four%.
driven by the strength in operating income, fourth quarter earnings per share grew num-one% to $num-two with the full year up num-three% to $num-four.